ArticleCancer medicine2026
Cancer Expenditures and Mortality Trends in Brazil: An Ecological Population-Level Time-Series Analysis, 2008-2023.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundBrazil has substantially expanded public oncology investment over the past decade, particularly within the Brazilian Unified Health System (SUS). However, whether increased spending has translated into measurable population-level improvements in cancer outcomes remains uncertain.
methodsWe conducted a retrospective ecological time-series analysis using national data from 2008 to 2023. Public expenditures for female breast and prostate cancer were extracted from DATASUS and inflation-adjusted, while mortality data were obtained from INCA and age-standardized. Key policy milestones-RDC 55/2010, creation of Conitec in 2011, Ordinance No. 874/2013, and Constitutional Amendment 95/2016-were mapped against expenditure and mortality trends. Findings therefore represent system-level associations rather than causal estimates of patient-level therapeutic effectiveness.
resultsOncology expenditures increased substantially, with more pronounced growth after 2011, whereas national age-standardized mortality rates for female breast and prostate cancer changed comparatively little. This pattern represents a descriptive temporal divergence between expenditure growth and mortality trends, not evidence of therapeutic inefficacy or a quantified causal effect. Regional differences in diagnostic capacity, healthcare infrastructure, continuity of care, and treatment timeliness may influence how financial inputs translate into population-level outcomes.
conclusionsBrazil's experience supports a value-oriented oncology strategy linking investment not only to technology incorporation, but also to early diagnosis, implementation capacity, regional equity, and effective care pathways. These ecological findings do not support individual-level causal inference, particularly for prostate cancer, for which mortality is a delayed and relatively insensitive medium-term endpoint. Future studies should incorporate stage at diagnosis, treatment pathways, time-to-treatment indicators, and regional survival data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.